|
 |
| DRUG WATCH |
|
|
|
| Year : 2014 | Volume
: 46
| Issue : 6 | Page : 651-652 |
| |
Hypoglycemia - A rare complication of carbamazepine overdose
Avanish Jha1, Kundavaram Paul Prabhakar Abhilash2, Rini Bandhyopadhyay2, Peter John Victor1
1 Medical Intensive Care Unit, Christian Medical College, Vellore, Tamil Nadu, India
2 Department of General Medicine, Christian Medical College, Vellore, Tamil Nadu, India
| Date of Submission | 24-Mar-2014 |
| Date of Decision | 24-May-2014 |
| Date of Acceptance | 28-Jul-2014 |
| Date of Web Publication | 18-Nov-2014 |
Correspondence Address:
Kundavaram Paul Prabhakar Abhilash
Department of General Medicine, Christian Medical College, Vellore, Tamil Nadu
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0253-7613.144941
Carbamazepine overdose usually presents with neurological manifestations such as ataxia, seizures and altered sensorium or cardiac manifestations that include tachycardia, hypotension and ventricular extra-systoles. We report a patient with carbamazepine overdose who manifested recurrent hypoglycemia on the third and fourth day following ingestion that resolved with supportive therapy.
Keywords: Anti-epileptic, carbamazepine, complication, hypoglycemia, overdose
How to cite this article:
Jha A, Abhilash KP, Bandhyopadhyay R, Victor PJ. Hypoglycemia - A rare complication of carbamazepine overdose
. Indian J Pharmacol 2014;46:651-2 |
| » Introduction | |  |
Carbamazepine, a first line antiepileptic belonging to the iminostilbene group, contributes to 46.9% of antiepileptic drug overdose in the United Kingdom. [1] Overdose results in neurologic, cardiac and metabolic manifestations. [1] We report the occurrence of recurrent and protracted hypoglycemia in the setting of carbamazepine overdose.
| » Case Report | | |
A 20-year-old pregnant woman at 26-weeks of gestation, on anti-epileptic therapy with carbamazepine presented with a history of consumption of 4000 mg (200 mg × 20 tablets) of carbamazepine. She denied concomitant overdose with other medications. Following gastric lavage at a local hospital, she was transferred to our hospital 4-hours after ingestion. At presentation Glasgow coma score (GCS) was 3/15, pulse rate was 138/min, blood pressure 110/70 mmHg and respiratory rate 25/min. Capillary blood glucose level was 109 mg/dl. Pupils were dilated 6 mm bilaterally and reacting to light. Deep tendon reflexes were sluggish and Babinski sign was negative. Rest of systemic examination was unremarkable. She was intubated for low sensorium. Multi-dose activated charcoal therapy (50 grams every 6 hours) was administered. She was shifted to the intensive care unit (ICU) for ventilation and monitoring.
Serum carbamazepine level was > 20 μg/ml (therapeutic level 6-12 μg/ml). Hemoglobin was 8 g/dl and white count 15,200/cumm. Renal function, liver function test and coagulation profile were within normal limits. Six hours into admission she developed circulatory shock requiring fluid resuscitation and low dose vasopressors. Empiric antibiotic therapy was initiated, which was subsequently discontinued in view of negative cultures, low procalcitonin (0.34) and absence of a definite focus of infection.
On the third day, several episodes of hypoglycemia were observed [Figure 1] which was managed initially with bolus doses of 50% dextrose for each episode and subsequently with an infusion of 25% dextrose. The infusion was given for 60 hours following which there were no further episodes of hypoglycemia. Other causes of hypoglycemia including drugs, renal or hepatic failure and sepsis were ruled out. Serum carbamazepine level on the third day was still elevated (17.3 μg/ml) and decreased to sub therapeutic range by the seventh day (2.97 μg/ml).
By day 7, she was extubated and vasoactive agents were weaned. Serum carbamazepine level showed a declining trend and normalized. At 2-months follow-up no further hypoglycemic episodes were documented.
| » Discussion | | |
Carbamazepine a drug used for the treatment of trigeminal neuralgia and epilepsy acts by preventing repeated firing of the neurons by prolonging the inactive state of the sodium channels. The maintenance dose is 15-20 mg/kg. Oral absorption is slow and variable due to poor water solubility. It is highly protein bound (75%) and is metabolized in liver by CYP 3A4. It is an inducer of CYP 3A4 and this auto-induction requires up-scaling of doses in chronic use.
Carbamazepine may produce rash and photosensitivity but serious idiosyncratic reactions such as drug-induced lupus and agranulocytosis are relatively rare. [2] Acute overdose results in neurotoxicity and cardiac collapse. Neurological symptoms include ataxia, nystagmus, seizures, status epilepticus and altered sensorium. [3],[4] Cardiotoxicity manifests as tachycardia, hypotension and ventricular extra systoles. [5] Acute hypernatremia, a rare complication of overdose is due to inappropriate anti-diuretic hormone secretion. [6] Hepatotoxicity, common with chronic use is rare in acute overdose. [7]
Our patient had neurotoxicity and cardiotoxicity as evidenced by depressed sensorium and prolonged circulatory shock with tachycardia. Recurrent and protracted hypoglycemia, which our patient manifested, has not been reported following overdose. The mechanism of hypoglycemia was unclear. Although valproic acid can cause hyperinsulinemia, [8] there is no evidence that carbamazepine impacts insulin levels. Thus possible mechanisms for hypoglycemia include increased insulin secretion, decreased gluconeogenesis, increased glucose utilization and storage or decreased glucagon release. Increased fetal glucose demand may have contributed to hypoglycemia; the absence of hypoglycemic episodes following recovery from the overdose however suggests other mechanism (s) for hypoglycemia. Measurement of plasma insulin levels may have helped in ascertaining the mechanism of hypoglycemia, however this was not done for our patient.
| » Conclusion | | |
Hypoglycemiamay be encountered in carbamazepine overdose. Clinicians need to be aware of this complication and monitor blood glucose in those who present with toxicity.
| » References | | |
| 1. | Nixon AC, Doak MW, Crozier H, Crooks DP, Waring WS. Patterns of antiepileptic drug overdose differ between men and women: Admissions to the Edinburgh Poisons Unit, 2000-2007. QJM 2009;101:51-6.  |
| 2. | Daughton JM, Padala PR, Gabel TL. Careful monitoring for agranulocytosis during carbamazepine treatment. Prim Care Companion J Clin Psychiatry 2006;8:310-1. |
| 3. | Lifshitz M, Gavrilov V, Sofer S. Signs and symptoms of carbamazepine overdose in young children. Pediatr Emerg Care 2000;16:26-7. |
| 4. | Spiller HA, Carlisle RD. Status epilepticus after massive carbamazepine overdose. J Toxicol Clin Toxicol 2002;40:81-90. |
| 5. | Todoroviæ V, Randeloviæ S, Joksoviæ D, Joviæ-Stosiæ J, Vuciniæ S, Glisoviæ L. Carbamazepine cardiotoxicity in acute poisoning. Vojnosanit Pregl 1993;50:143-6. |
| 6. | Thabet H, Brahmi N, Zagdoudi I, Amamou M, Hedhili A, Ben Salah N, et al. Acute self‐poisoning with carbamazepine. Presse Med 1999;28:955-8. |
| 7. | Martínez P, González de Etxabarri S, Ereño C, López G, Hinojal C, Teira R. Acute severe hepatic insufficiency caused by carbamazepine. Rev Esp Enferm Dig 1993;84:124-6. |
| 8. | Belcastro V, D'Egidio C, Striano P, Verrotti A. Metabolic and endocrine effects of valproic acid chronic treatment. Epilepsy Res 2013;107:1-8. |
[Figure 1]
| This article has been cited by | | 1 |
Carbamazepine overdose |
|
| | | Reactions Weekly. 2015; 1533(1): 112 | | [Pubmed] | [DOI] | |
|
|
|
|
